News
You can now express your interest in IPCEI Health!
IPCEI stands for Important Projects of Common European Interest.
Een primeur in de geschiedenis van de Nationale Zorginnovatieprijs: Helpsoq wint zowel de vakjury- als de publieksprijs!
De innovatie Helpsoq is unaniem uitgeroepen tot de winnaar van de Nationale Zorginnovatieprijs 2022. Tijdens de uitreiking op het Health Valley Event werd Helpsoq aangekondigd als winnaar van zowel de vakjuryprijs ter waarde van €10.000,- als de publieksprijs ter waarde van €5.000,-. Een unicum in de geschiedenis van deze prijs.
Venture Challenge Alumnus Bi/ond has closed over $4+ Million in funding to date led by FORWARD.one
Organ-on-a-chip succes with leading European research institutioins fuels Bi/ond Investment.
Venture Challenge Alumnus TargED raises €39 million in a series A investment round
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients.
Pharmaceutical product based on SeraNovo's eutectic formulation enters clinical study
Venture Challenge winner SeraNovo is proud to announce that in December 2021, Carna Biosciences initiated a clinical study with a drug product based on a joint development program with SeraNovo's eutectic formulation technology.
Two free slots available for the Paul Janssen Futurelab blended course Clinical Development!
J&J Pharmaceuticals pays the course fee for 2 graduated biomedical professionals for their participation in the Paul Janssen Futurelab blended course Clinical Development.
Meet the teams of the Proefdiervrij Venture Challenge 2022
Following the successful first edition in 2021, Stichting Proefdiervrij is organising the second edition of the Proefdiervrij Venture Challenge from February - April 2022. During the Proefdiervrij Venture Challenge, these teams of researchers, are g
Venture Challenge Winner Hybridize Enters Agreement for a Direct-acting RNA-based Therapy Against BK Virus
AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus.
Venture Academy 2022
Join the Venture Academy Programme, a three-month programme where you can follow a specialised unlock_ track tailored for the Life Sciences and Health.
Venture Challenge alumnus Core Life Analytics signes collaboration with Molecule Devices
Molecular Devices and Core Life Analytics collaborate, adding the StratoMineR cloud-powered data analytics software to Molecular Devices' high-content portfolio Complementing Molecular Devices’ high-content imaging workflow, StratoMineR intuit